Menactra Approval Awaits Final Manufacturing Clearance
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis says it is prepared to produce a limited supply of the meningococcal conjugate vaccine soon after licensure. To meet expanded demand, the company is constructing a new Menactra manufacturing facility that will be fully operational in two to three years.
You may also be interested in...
Menactra Launch Slated For March On Heels Of Broad CDC Recommendations
Advisory Committee on Immunization Practices recommends routine meningococcal vaccination for adolescents ages 11-12, those entering high school and college freshmen living in dorms. Panel acknowledges that broad recommendations could lead to supply constraints, Sanofi says.
Menactra Launch Slated For March On Heels Of Broad CDC Recommendations
Advisory Committee on Immunization Practices recommends routine meningococcal vaccination for adolescents ages 11-12, those entering high school and college freshmen living in dorms. Panel acknowledges that broad recommendations could lead to supply constraints, Sanofi says.
Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar